Skip to content

Evaluation of therapeutic effect of compound Danshen dripping pills in the treatment of stable exertional angina pectoris.

Evaluation of therapeutic effect of compound Danshen dripping pills in the treatment of stable exertional angina pectoris.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17012014
Enrollment
Unknown
Registered
2017-07-17
Start date
2017-11-01
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable exertional angina pectoris

Interventions

Aspirin:Aspirin oral 100mg Qd
Combination:Danshen dripping pills oral 10pills Tid and Aspirin oral 100mg Qd

Sponsors

Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Male and female aged 18 to 70 years; 2. Patients with stable angina pectoris of coronary heart disease (Class I or II), angina more than 2 times per week attack I ~ III stable fatigue angina pectoris diagnosis; 3. Syndrome Differentiation of TCM is Blood Stasis Syndrome (including Complex syndromessuch as Qi Deficiency and Blood Stasis Syndrome); 4. ECG examination showed ischemic changes or exercise test results; 5. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with Acute coronary syndrome,or Severe angina pectoris and other cardiac disease, Severe neurosis, Menopausal syndrome, Cervical spondylosis; 2. patients with above level II high blood pressure, severe cardiopulmonary function is not complete; severe arrhythmia(rapid atrial fibrillation and flutter, paroxysmal ventricular tachycardia and so on); 3. patients with liver, renal, hemopoietic system failure; 4. Males and females younger than 18 years or older than 70 years; 5. patients within 4 weeks of surgery and have bleeding tendency, or long-term use of clopidogrel, and warfarin anticoagulant except aspirin; 6. Participation in any other clinical trial or receipt of an investigational drug within 30 days prior to the initial visit.

Design outcomes

Primary

MeasureTime frame
symptoms;physical sign;Blood coagulation;ECG;

Secondary

MeasureTime frame
tongue sign;pulse sign;Blood routine examination;

Countries

China

Contacts

Public ContactLIU ZHI

Tianjin University of Traditional Chinese Medicine

liuz@tice.com.cn+86 15822942943

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026